Updates in the Treatment of HR+ Breast Cancer - Episode 8

Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant

, , ,

A panel of experts discuss navigating 2L treatment strategies.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Expert Insights on Biomarker Testing in Early-Stage Breast Cancer
    EP. 2: Insights from TAILORx and RxPONDER in Guiding Treatment in Early-Stage HR+ Breast Cancer
    EP. 3: Advancements in Adjuvant Therapy in Early-Stage HR+ Breast Cancer
    EP. 4: Expert Perspectives on Optimizing Biomarker Testing in Advanced HR+/HER2- Breast Cancer
    EP. 5: Potential With Individual Tumor Sequencing With Bespoke Testing Methodologies and ctDNA
    EP. 6: Updates in Treatment Approaches With CDK4/6 Inhibitors in HR+ Breast Cancer
    EP. 7: Expert Perspectives in Navigating Treatment Strategies with CDK4/6 Inhibitors in HR+ Breast Cancer
    Now Viewing
    EP. 8: Navigating 2L Treatment Strategies with Oral SERDs and Elasestrant
    EP. 9: Treatment Advancements Targeting the PI3K/AKT Pathway in HR+ Breast Cancer
    EP. 10: ADC-Based Treatment Strategies HR+Breast Cancer:Updates from DESTINY-Breast06
    EP. 11: Expert Perspectives in Sequencing ADC-Based Therapies in HR+ Breast Cancer
    EP. 12: Looking Ahead: Expert Future Perspectives in the HR+ Breast Cancer Landscape

    Video content above is prompted by the following:

    • What are your perceptions on efficacy and safety data on PROTAC
    • What are your perceptions on efficacy and safety data on SERM:
      • Lasoxifene: ASCO 2024 #TPS1127: Phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib
    • How do these options compare? Why might you choose one of these options vs fulvestrant?
    x